Ocumension Therapeutics
HKEX:1477

Watchlist Manager
Ocumension Therapeutics Logo
Ocumension Therapeutics
HKEX:1477
Watchlist
Price: 4.41 HKD 0.46%
Market Cap: 3.6B HKD
Have any thoughts about
Ocumension Therapeutics?
Write Note

Operating Margin
Ocumension Therapeutics

-111.2%
Current
-323%
Average
6.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-111.2%
=
Operating Profit
-344.9m
/
Revenue
310.3m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
CN
Ocumension Therapeutics
HKEX:1477
3.6B HKD
-111%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-83%
US
Eli Lilly and Co
NYSE:LLY
755.8B USD
35%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK
44%
US
Johnson & Johnson
NYSE:JNJ
351.1B USD
28%
US
Merck & Co Inc
NYSE:MRK
251.8B USD
34%
CH
Roche Holding AG
SIX:ROG
200.1B CHF
32%
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP
21%
CH
Novartis AG
SIX:NOVN
171.5B CHF
31%
US
Pfizer Inc
NYSE:PFE
151.5B USD
22%
Country CN
Market Cap 3.6B HKD
Operating Margin
-111%
Country JP
Market Cap 776 550.9T JPY
Operating Margin
-83%
Country US
Market Cap 755.8B USD
Operating Margin
35%
Country UK
Market Cap 440.4B GBP
Operating Margin
3%
Country DK
Market Cap 2.7T DKK
Operating Margin
44%
Country US
Market Cap 351.1B USD
Operating Margin
28%
Country US
Market Cap 251.8B USD
Operating Margin
34%
Country CH
Market Cap 200.1B CHF
Operating Margin
32%
Country UK
Market Cap 161.8B GBP
Operating Margin
21%
Country CH
Market Cap 171.5B CHF
Operating Margin
31%
Country US
Market Cap 151.5B USD
Operating Margin
22%
No Stocks Found

Ocumension Therapeutics
Glance View

Market Cap
3.6B HKD
Industry
Pharmaceuticals

Ocumension Therapeutics engages in the identification, development, and commercialization of ophthalmic therapies. The company is headquartered in Suzhou, Jiangsu. The company went IPO on 2020-07-10. Its main products include OT-401 (YUTIQ), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-301 (NCX 470), OT-101 and OT-202, among others. The firm conducts its businesses in the domestic market.

Intrinsic Value
5.8 HKD
Undervaluation 24%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-111.2%
=
Operating Profit
-344.9m
/
Revenue
310.3m
What is the Operating Margin of Ocumension Therapeutics?

Based on Ocumension Therapeutics's most recent financial statements, the company has Operating Margin of -111.2%.